Zynerba Pharmaceuticals has been acquired by Harmony Biosciences, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases. For more information on Harmony and the acquisition, please click here
The RECONNECT Trial is continuing uninterrupted with Harmony Biosciences
What is Fragile X Syndrome (FXS)?
Fragile X Syndrome (FXS) is a rare genetic disorder carried on the X chromosome that causes:
- Intellectual disability
- Anxiety
- Behavioral challenges
- Learning challenges
- Physical characteristics (such as: longer face, larger ears, etc.)
FXS is diagnosed with a genetic blood test.
FXS affects both males and females; females often have milder symptoms than males.
Do you care for an individual ages 3 to 22 years old with the following behaviors of FXS?
- Anxiety
- Irritability
- Tantrums
- Learning challenges
If your child has FXS, a clinical trial may be an option for your family.
Now Enrolling:
Fragile X Syndrome Study (RECONNECT)
Complete the form below OR Call us at 1‑833‑680‑1155
The RECONNECT study is evaluating an investigational, topical gel to address behavioral issues related to Fragile X syndrome (FXS).
The trial is currently enrolling:
- people ages 3 to 22 with a genetic diagnosis of Fragile X syndrome
- who are experiencing behavioral symptoms
- and are in generally good health
Complete the form below to learn more and see if you or someone you love may be eligible to participate either at a clinic trial site OR ALL from your home.
To learn more to see if you or someone you love may be eligible to participate either at a clinic trial site OR ALL from your home you can either:
You will receive a call back from our team after you submit the above form to discuss the RECONNECT trial, your preference to participate at a trial site OR at home and if you or your loved one are eligible to participate.
